A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Hereditary angioedema ("HAE") is a disease characterized by recurrent tissue swelling
affecting various body locations. Recent literature shows that patients with frequent attacks
may benefit from long-term prophylaxis. This study aims to evaluate the safety and
prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor
("rhC1INH").
Phase:
Phase 2
Details
Lead Sponsor:
Pharming Technologies B.V.
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein